Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-07-09FDA Approved: DARZALEX FASPRO — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) from Janssen Biotech, Inc.
-
FDA approval · 2021-07-09FDA Approved: DARZALEX — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved a supplemental application for DARZALEX (daratumumab) filed by Janssen Biotech, Inc., resulting in an updated labeling.
-
CLINICAL_TRIALS withdrawal · 2021-07-09Clinical Trial Update: Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma [Phase 3]
Phase 3 trial of Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone for first-line treatment in multiple myeloma was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-07-08Clinical Trial Update: Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma [Phase 3]
Phase 3 trial evaluating bortezomib, selinexor, and dexamethasone in relapsed/refractory multiple myeloma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-01Clinical Trial Update: PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy) [Phase 3]
Phase 3 study evaluating lenalidomide and dexamethasone with or without elotuzumab in newly diagnosed, untreated multiple myeloma; trial ter…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-06-30Clinical Trial Update: A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating venetoclax with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma was terminated; results p…
-
EMA approval · 2021-06-25First cell-based gene therapy to treat adult patients with multiple myeloma
EMA announces first cell-based gene therapy authorized to treat adult patients with multiple myeloma, marking a milestone in advanced cellul…
-
CLINICAL_TRIALS trial_result · 2021-06-22Clinical Trial Update: UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission [Phase 2]
Phase 2 trial in high-risk multiple myeloma was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial update for ABC294640 (Opaganib) in refractory/relapsed multiple myeloma; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) [Phase 2]
Phase 2 exploratory trial evaluating tumor cell contamination in leukapheresis products with and without Bortezomib in multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Tinostamustine Conditioning and Autologous Stem Cell [Phase 1, Phase 2]
Phase 1/2 study of tinostamustine conditioning with autologous stem cell transplantation in relapsed or progressing multiple myeloma; trial …
-
CLINICAL_TRIALS trial_result · 2021-06-15Clinical Trial Update: Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma [Phase 3]
Phase 3 trial update evaluating frailty-adjusted therapy for transplant non-eligible patients with newly diagnosed multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: Unrelated Umbilical Cord Blood (UBC)Transplantation [NA]
Clinical trial update for unrelated umbilical cord blood transplantation; the study is completed with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-06-07Clinical Trial Update: Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients [Phase 2]
Phase 2 clinical trial investigating propranolol to reduce stress-mediated gene expression pathways in hematopoietic stem cell transplant re…
-
FDA approval · 2021-05-28FDA Approved: POMALIDOMIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for pomalidomide by Aurobindo Pharma Limited under the ANDA process.
-
CLINICAL_TRIALS trial_result · 2021-05-27Clinical Trial Update: Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma [Phase 2]
Phase II study update evaluating a combination of Biaxin, Revlimid, and dexamethasone for untreated multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2021-05-26Clinical Trial Update: Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants [Phase 4]
Phase 4 clinical trial evaluating zoledronic acid given every 4 or 12 weeks to prevent skeletal-related events in advanced multiple myeloma;…
-
CLINICAL_TRIALS trial_result · 2021-05-21Clinical Trial Update: Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma [Phase 2]
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for multiple myeloma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-05-19Clinical Trial Update: Safety and Efficacy Assessments of Osalmid in Multiple Myeloma [Phase 1, Phase 2]
Early-phase clinical trial update evaluating safety and efficacy of Osalmid in patients with Multiple Myeloma (Phase 1/2).
-
CLINICAL_TRIALS trial_result · 2021-05-18Clinical Trial Update: Selinexor in Combination With Thalidomide and Dexamethasone in RRMM [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating selinexor in combination with thalidomide and dexamethasone for relapsed/refractory multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2021-05-14Clinical Trial Update: UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment [Phase 2]
Phase II prospective evaluation of bone remodeling during ixazomib treatment in patients with multiple myeloma completed with results posted…
-
CLINICAL_TRIALS trial_result · 2021-05-10Clinical Trial Update: Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma [NA]
Clinical trial update describing a study of bortezomib and filgrastim to promote stem cell mobilization in patients with various B-cell non-…
-
FDA approval · 2021-04-30FDA Approved: CARMUSTINE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for Carmustine submitted by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. This actio…
-
CLINICAL_TRIALS trial_result · 2021-04-30Clinical Trial Update: Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) [Phase 3]
A Phase 3 trial evaluating vorinostat (MK-0683) or placebo plus bortezomib in participants with multiple myeloma has completed with results …
-
CLINICAL_TRIALS trial_result · 2021-04-28Clinical Trial Update: An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients [Phase 2]
Phase 2 trial evaluating intensive quadruplet induction and consolidation with tandem autologous stem cell transplantation in newly diagnose…